{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:04:35Z","timestamp":1761102275850},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T00:00:00Z","timestamp":1499731200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Institute of Health","award":["Building Interdisciplinary Research in Women's Hea"],"award-info":[{"award-number":["Building Interdisciplinary Research in Women's Hea"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1245\/s10434-017-5995-z","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T09:02:52Z","timestamp":1499763772000},"page":"3116-3123","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer"],"prefix":"10.1245","volume":"24","author":[{"given":"Charlotte","family":"Gamble","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Havrilesky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan R.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzo P.","family":"Chino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Hollenbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer K.","family":"Plichta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Kelly Marcom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Shelley Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah D.","family":"Kauff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel A.","family":"Greenup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,11]]},"reference":[{"key":"5995_CR1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/sj.bjc.6600008","volume":"86","author":"AC Antoniou","year":"2002","unstructured":"Antoniou AC, Pharoah PDP, McMullan G, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002;86:76-83.","journal-title":"Br J Cancer."},{"issue":"6","key":"5995_CR2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2005.03.6772","volume":"24","author":"S Chen","year":"2006","unstructured":"Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006;24(6):863-871.","journal-title":"J Clin Oncol."},{"key":"5995_CR3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10549-010-0805-3","volume":"124","author":"DM Kolk van der","year":"2010","unstructured":"van der Kolk DM, de Bock GH, Leege BK, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat. 2010;124:643-651.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"5995_CR4","first-page":"265","volume":"56","author":"DF Easton","year":"1995","unstructured":"Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;56(1):265-271.","journal-title":"Am J Hum Genet."},{"issue":"21","key":"5995_CR5","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","volume":"346","author":"TR Rebbeck","year":"2002","unstructured":"Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616-1622.","journal-title":"N Engl J Med."},{"issue":"21","key":"5995_CR6","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","volume":"346","author":"ND Kauff","year":"2002","unstructured":"Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women iwht a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609-1615.","journal-title":"N Engl J Med."},{"issue":"3","key":"5995_CR7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200107193450301","volume":"345","author":"H Meijers-Heijboer","year":"2001","unstructured":"Meijers-Heijboer H, van Geel B, van Putten WLJ, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159-164.","journal-title":"N Engl J Med."},{"issue":"21","key":"5995_CR8","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","volume":"93","author":"LC Hartmann","year":"2001","unstructured":"Hartmann LC, Sellers TA, Shchaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93(21):1633-1637.","journal-title":"J Natl Cancer Inst."},{"key":"5995_CR9","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. 2017. \n                        http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp\n                        \n                    . Accessed 27 Feb 2017."},{"issue":"4","key":"5995_CR10","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.amjsurg.2016.06.010","volume":"212","author":"KK Ludwig","year":"2016","unstructured":"Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg. 2016;212(4):660-669.","journal-title":"Am J Surg."},{"issue":"5","key":"5995_CR11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrclinonc.2016.191","volume":"14","author":"A George","year":"2017","unstructured":"George A, Kaye S, Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol. 2017;14(5):284\u2013296.","journal-title":"Nat Rev Clin Oncol."},{"key":"5995_CR12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10549-010-1043-4","volume":"125","author":"VR Grann","year":"2011","unstructured":"Grann VR, Patel PR, Jacobson JS, et al. Comparative effectiveness of screening and prevention strategies among BRCA1\/2-affected mutation carriers. Breast Cancer Res Treat. 2011;125:837-847.","journal-title":"Breast Cancer Res Treat."},{"key":"5995_CR13","unstructured":"Society of Gynecologic Oncology. SGO Clinical Practice Statement: Genetic Testing for Ovarian Cancer. Society of Gynecologic Oncology; 2014."},{"key":"5995_CR14","unstructured":"Howlander N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975\u20132012. Based on November 2014 SEER data submission, posted to the SEER web site, April 2015. \n                        http:\/\/seer.cancer.gov\/csr\/1975_2012\/\n                        \n                    . Accessed 5 Jan 2016."},{"issue":"1","key":"5995_CR15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2007.11.6905","volume":"26","author":"A Chetrit","year":"2008","unstructured":"Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1\/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol. 2008;26(1):20-25.","journal-title":"J Clin Oncol."},{"issue":"21","key":"5995_CR16","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654-2663.","journal-title":"J Clin Oncol."},{"issue":"11","key":"5995_CR17","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","volume":"17","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579-1589.","journal-title":"Lancet Oncol."},{"issue":"22","key":"5995_CR18","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154-2164.","journal-title":"N Engl J Med."},{"issue":"10","key":"5995_CR19","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sander","year":"2016","unstructured":"Sander GD, Neumann PJ, Basu A, et al. Second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093-1103.","journal-title":"JAMA."},{"issue":"9","key":"5995_CR20","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness: the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796-797.","journal-title":"N Engl J Med."},{"issue":"25","key":"5995_CR21","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1200\/JCO.2007.13.1961","volume":"26","author":"LJ Havrilesky","year":"2008","unstructured":"Havrilesky LJ, Alvarez Secord A, Darcy KM, Armstrong DK, Kulasingam S. Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2008;26(25):4144-4150.","journal-title":"J Clin Oncol."},{"issue":"8","key":"5995_CR22","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/annonc\/mdt134","volume":"24","author":"BA Heemskerk-Gerritsen","year":"2013","unstructured":"Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol. 2013;24(8):2029-2035.","journal-title":"Ann Oncol."},{"issue":"1","key":"5995_CR23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2013.06.025","volume":"131","author":"LJ Havrilesky","year":"2013","unstructured":"Havrilesky LJ, Chino JP, Myers ER. How much is another randomized trial of lymph node dissection in endometrial cancer worth? A value of information analysis. Gynecol Oncol. 2013;131(1):140-146.","journal-title":"Gynecol Oncol."},{"issue":"14","key":"5995_CR24","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","volume":"306","author":"D Yang","year":"2011","unstructured":"Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011;306(14):1557-1565.","journal-title":"JAMA."},{"issue":"15","key":"5995_CR25","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.ejca.2014.07.015","volume":"50","author":"ME Burg van der","year":"2014","unstructured":"van der Burg ME, Onstenk W, Boere IA, et al. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel\/platinum induction therapy followed by standard or extended three-weekly paclitaxel\/platinum in European patients with advanced epithelial ovarian cancer. Eur J Cancer. 2014;50(15):2592-2601.","journal-title":"Eur J Cancer."},{"issue":"1","key":"5995_CR26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/1078-0432.CCR-14-1816","volume":"21","author":"Q Zhong","year":"2015","unstructured":"Zhong Q, Peng HL, Zhao X, Zhang L, Hwang WT. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res. 2015;21(1):211-220.","journal-title":"Clin Cancer Res."},{"issue":"1","key":"5995_CR27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","volume":"139","author":"C Aghajanian","year":"2015","unstructured":"Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015;139(1):10-16.","journal-title":"Gynecol Oncol."},{"issue":"9","key":"5995_CR28","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","volume":"20","author":"SR Lakhani","year":"2002","unstructured":"Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9):2310-2318.","journal-title":"J Clin Oncol."},{"issue":"6","key":"5995_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-014-0474-y","volume":"16","author":"AB Spurdle","year":"2014","unstructured":"Spurdle AB, Couch FJ, Parsons MT, et al. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res. 2014;16(6):1.","journal-title":"Breast Cancer Res."},{"issue":"15","key":"5995_CR30","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429-4434.","journal-title":"Clin Cancer Res."},{"issue":"11","key":"5995_CR31","first-page":"1","volume":"64","author":"E Arias","year":"2015","unstructured":"Arias E. United States Life Tables, 2011. Natl Vital Stat Rep. 2015;64(11):1\u201363.","journal-title":"Natl Vital Stat Rep."},{"key":"5995_CR32","unstructured":"Halfhill TR. Tom\u2019s Inflation Calculator. 2016. \n                        http:\/\/www.halfhill.com\/inflation_js.html\n                        \n                    . Accessed 23 May 2015."},{"key":"5995_CR33","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1001\/jama.295.20.2374","volume":"295","author":"SK Plevritis","year":"2006","unstructured":"Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1\/2 mutation carrierw with breast magnetic resonance imaging. JAMA. 2006;295:2374-2384.","journal-title":"JAMA."},{"issue":"22","key":"5995_CR34","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.2011.35.6956","volume":"29","author":"B Zendejas","year":"2011","unstructured":"Zendejas B, Moriarty JP, O\u2019Byrne J, Degnim AC, Farley DR, Boughey JC. Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer. J Clin Oncol. 2011;29(22):2993-3000.","journal-title":"J Clin Oncol."},{"issue":"2","key":"5995_CR35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/SAP.0b013e318276d979","volume":"73","author":"AM Fitzpatrick","year":"2014","unstructured":"Fitzpatrick AM, Gao LL, Smith BL, et al. Cost and outcome analysis of breast reconstruction paradigm shift. Ann Plast Surg. 2014;73(2):141-149.","journal-title":"Ann Plast Surg."},{"issue":"6","key":"5995_CR36","doi-asserted-by":"crossref","first-page":"730e","DOI":"10.1097\/PRS.0000000000001763","volume":"136","author":"D Mattos","year":"2015","unstructured":"Mattos D, Gfrerer L, Reish RG, et al. Lifetime costs of prophylactic mastectomies and reconstruction versus surveillance. Plast Reconstr Surg. 2015;136(6):730e-740e.","journal-title":"Plast Reconstr Surg."},{"issue":"9","key":"5995_CR37","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/jnci\/djn103","volume":"100","author":"KR Yabroff","year":"2008","unstructured":"Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100(9):630-641.","journal-title":"J Natl Cancer Inst."},{"issue":"5","key":"5995_CR38","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/cncr.27839","volume":"119","author":"PM Vencken","year":"2013","unstructured":"Vencken PM, Kriege M, Hooning M, et al. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1\/BRCA2 mutation carriers: implications for counseling. Cancer. 2013;119(5):955-962.","journal-title":"Cancer."},{"issue":"12","key":"5995_CR39","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamasurg.2014.1081","volume":"149","author":"A Gangi","year":"2014","unstructured":"Gangi A, Cass I, Paik D, et al. Breast cancer following ovarian cancer in brca mutation carriers. JAMA Surg. 2014;149(12):1306-1313.","journal-title":"JAMA Surg."},{"issue":"7","key":"5995_CR40","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/cncr.27842","volume":"119","author":"SM Domchek","year":"2013","unstructured":"Domchek SM, Jhaveri K, Patil S, et al. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer. 2013;119(7):1344-1348.","journal-title":"Cancer."},{"issue":"2","key":"5995_CR41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ygyno.2015.11.030","volume":"140","author":"LE Minion","year":"2016","unstructured":"Minion LE, Coleman RL, Alvarez RD, Herzog TJ. Endpoints in clinical trials: what do patients consider important? A survey of the Ovarian Cancer National Alliance. Gynecol Oncol. 2016;140(2):193-198.","journal-title":"Gynecol Oncol."},{"issue":"44","key":"5995_CR42","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","volume":"108","author":"T Walsh","year":"2011","unstructured":"Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032-18037.","journal-title":"Proc Natl Acad Sci USA."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-017-5995-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-017-5995-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-017-5995-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T14:39:32Z","timestamp":1505227172000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-017-5995-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,11]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["5995"],"URL":"https:\/\/doi.org\/10.1245\/s10434-017-5995-z","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,11]]}}}